FilingReader Intelligence

North China Pharmaceutical gets drug registration after 1.1bn yuan investment

July 29, 2025 at 09:12 AM UTCBy FilingReader AI

North China Pharmaceutical received a drug registration certificate for its Cobamamide Capsules from the National Medical Products Administration.

The company invested 1.09 billion yuan in developing the product. Twenty-seven companies in China now hold registration certificates for this specific dosage.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when North China Pharmaceutical publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →